Bio Green Med Solution holds special shareholder meeting
BGMS•Bio Green Med Solution shareholders approved the share issuance and related change of control under the Future NRG business combination agreement at a November 19, 2026, special meeting. They also approved an increase in authorized common stock to 3 billion shares, a reverse split of 1-for-4 to 1-for-16, and financing authority for 24 months after the transaction.
1. Shareholder approvals
Shareholders approved issuing shares under the Future NRG business combination agreement, including issuance exceeding 20% of outstanding common stock and the associated change of control. They also approved increasing authorized common stock to 3 billion shares and authorized a reverse stock split at a ratio selected by the board between 1-for-4 and 1-for-16.
2. Future financing
The approvals also cover issuing common stock, warrants and other securities linked to common stock during the 24-month period following the transaction.




